Dan Nandan is the Founder and CEO of Staffingly, Inc., based in US-based. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, workflows.
Featured in Computerworld →
State of Florida. Licensed Pharmacist. AHA Certified Immunizer
Shammi Chapalamadugu is a Florida-licensed pharmacist (MS, RPh) with more than 20 years across retail pharmacy, clinical operations, and patient care coordination, and is an AHA certified immunizer. He reviews this pharmacy and medication prior-authorization content for accuracy, drug-coverage context, and compliance.
What Is Repatha prior authorization?
Repatha (evolocumab) is a PCSK9 inhibitor manufactured by Amgen. It blocks the PCSK9 protein, allowing LDL receptors on liver cells to clear more LDL cholesterol from the bloodstream. Patients self-inject 140 mg every two weeks or 420 mg once monthly, depending on the prescribed regimen.
Repatha PA Criteria by Payer Type
While every insurer publishes its own PCSK9 inhibitor coverage policy, requirements vary by payer, plan, indication, and current drug-coverage policy. Some plans require additional lipid-lowering therapy or documented intolerance, while others use statin history and LDL-C thresholds. Understanding the common building blocks prevents documentation gaps that cause many denials, but always confirm the plan’s published policy before submission.
Clinical documentation required by most payers
- Confirmed diagnosis: documented ASCVD, HeFH, HoFH, or elevated LDL-C with increased MACE risk (per 2025 expanded label)
- Maximally tolerated statin trial: many payers require a documented trial on the highest tolerated statin dose; required duration varies by policy. Document the specific statin, dose, duration, and reason for dose limitation (myalgia, CK elevation, hepatotoxicity, rhabdomyolysis risk)
- Ezetimibe or additional lipid-lowering therapy: many payers require an ezetimibe trial (or documented intolerance) in combination with maximally tolerated statin before approving a PCSK9 inhibitor, while some plans instead rely on statin history and LDL-C thresholds. Confirm the plan’s current policy
- Background therapy and LDL-C thresholds: Requirements vary by payer, plan and indication. Document the patient’s statin history, intolerance when applicable, current LDL-C level and any additional lipid-lowering therapy required by the current policy
- Lipid panel within 30-90 days: a current fasting lipid panel showing LDL-C above the payer’s threshold is required with submission
- Prescriber qualification: many plans prefer or require a cardiologist, lipidologist, or endocrinologist, and some accept primary care with documented specialist consultation; confirm the plan’s requirement
Payer-specific examples:
- Cigna: coverage pathways in Cigna’s PCSK9 inhibitor policy include documented ASCVD or familial hypercholesterolemia with high-intensity statin therapy, statin intolerance, or a qualifying diagnosis plus LDL-C thresholds; ezetimibe is not a universal prerequisite. Verify against Cigna’s current PCSK9 Inhibitors (Repatha) prior authorization policy and confirm its effective/review date before relying on it
- Other payers (for example, UnitedHealthcare): a qualifying ASCVD/HeFH/HoFH diagnosis, a documented statin trial, LDL-C above specified thresholds, and peer-to-peer review available for denials. Required durations and step-therapy agents differ by plan, so confirm the payer’s current published policy and its effective or review date
Reauthorization: Most payers require reauthorization every 6-12 months with updated lipid panels and documentation of adherence. Set calendar reminders 30 days before expiration.
Step-by-Step Repatha PA Process
JAMA Cardiology research shows PCSK9 inhibitors require 3-11 times more documentation items than other cardiometabolic drugs. Front-loading every required document saves weeks. And when a submission goes quiet, this is where specialty-drug prior authorizations actually sit during weeks of no answer .
Step 1: Verify eligibility and formulary status. Log into the payer portal or call the pharmacy benefits line. Confirm drug coverage is active, check whether Repatha is on formulary (preferred vs. non-preferred vs. excluded), and identify step therapy requirements. If Praluent or Leqvio is the preferred PCSK9 inhibitor, determine whether a medical exception is needed.
Step 2: Gather all clinical documentation. Before submitting, collect: diagnosis with the ICD-10 code supported by the patient’s documented diagnosis (E78.011 for heterozygous familial hypercholesterolemia, E78.010 for homozygous, E78.00 for pure hypercholesterolemia unspecified; code ASCVD to the specific atherosclerotic condition documented, for example I25.10 for atherosclerotic heart disease of native coronary artery), current fasting lipid panel (within 30-90 days), statin trial history with dates/doses/outcomes, ezetimibe trial history, letter of medical necessity from the prescribing cardiologist, relevant cardiac history (prior MI, stent, CABG, stroke), and prescriber NPI.
Step 3: Submit the PA request. Use the payer’s electronic portal or CoverMyMeds. Attach all clinical documentation with the initial request. Do not submit a partial request and plan to send records later. Incomplete submissions are a frequent cause of PCSK9 inhibitor denials.
Step 4: Track the request. Drug PA decision timeframes are set by the payer, plan type, and pharmacy benefit manager rather than a single federal deadline, so confirm the plan’s stated turnaround when you submit. Monitor the portal daily. If the payer requests additional information, respond within 24 hours.
Step 5: Document the outcome. Record the approval number, authorized dates, approved quantity, and any conditions. Set a reauthorization reminder 30 days before expiration.
Parallel action: Eligible patients may have access to financial-support resources through Amgen SupportPlus. Eligibility, benefit amounts, exclusions and program limits apply and should be confirmed through the current official program terms.
Get a free Repatha PA assessment
Tell us your payer mix and volume, or book a strategy call and talk it through live. We map the fastest path to first-pass approval.
Form not loading? Call (800) 489-5877 or book directly at staffingly.com/demo .
Common Repatha Denial Reasons and How to Appeal
Pharmacy Times reported PCSK9 inhibitors had a 30.95% rejected prescription rate between 2015 and 2021, more than double the rate for other branded cardiometabolic drugs. Knowing the specific denial reasons builds stronger initial submissions. Denials that slip through are not always lost revenue either; here is what can still get paid after a no-auth denial .
Step therapy not completed. The payer says the patient has not tried maximally tolerated statin + ezetimibe. Document each statin trial separately with start date, end date, dose, side effects, and objective findings (CK levels, ALT/AST). Include ezetimibe trial dates and LDL-C response. If the patient has a contraindication to statins, provide the clinical basis through a step therapy override request.
LDL-C threshold not met. The submitted lipid panel shows LDL-C below the payer’s threshold. Confirm the payer’s exact LDL-C threshold before submitting (some payers use 70 mg/dL for ASCVD, others use 100 mg/dL). Submit the most recent lipid panel drawn while on maximally tolerated background therapy.
Incomplete documentation. The payer received the request but is missing required clinical records. Submit every document listed in the payer’s PCSK9 criteria checklist with the initial request. Do not assume the payer will reference records from prior authorization periods.
Non-qualifying diagnosis. The ICD-10 code does not match the payer’s covered indications. Ensure the code matches the payer’s criteria. Reference the 2025 expanded FDA label if submitting for elevated LDL-C with increased MACE risk.
The appeal process: Most payers allow 60-180 days to file an appeal. Submit a written appeal addressing the specific denial reason, include all original documentation plus additional evidence, and request a peer-to-peer review with the payer’s medical director. Include citations from the FOURIER trial and ACC/AHA guidelines. In 2024, 80.7% of appealed Medicare Advantage denials were overturned, per KFF analysis of CMS data, though only about 11.5% of denials are ever appealed. That figure covers all Medicare Advantage prior authorizations, not Repatha, PCSK9 inhibitors, or any vendor’s performance. If peer-to-peer callbacks are eating your clinic hours, see how practices stop peer-to-peer reviews from consuming the schedule .
Save approximately 68% with dedicated PA specialists
Book a 15-minute call. We will map your current prior authorization workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
Repatha Medicaid Coverage: New York, New Jersey, and California
New York: NY Medicaid maintains a PDL administered through the Drug Utilization Review Board (DURB) requiring clinical PA for PCSK9 inhibitors. NY Medicaid MCOs (Fidelis, Healthfirst, Amerigroup NY, UHC Community Plan) each have separate formularies and PA portals. verify Repatha coverage with the patient’s specific MCO before submitting. NY’s Prescription Drug Formulary Transparency Act requires insurers to disclose formulary changes 60 days in advance, giving providers lead time to adjust PA strategies. Source: NY Medicaid Pharmacy
New Jersey: NJ FamilyCare maintains a PDL with PA requirements through DMAHS. NJ Medicaid MCOs (Horizon NJ Health, Aetna Better Health NJ, WellCare NJ, Amerigroup NJ, UHC Community Plan NJ) maintain separate formularies. Each MCO sets its own drug PA timelines and forms. PA criteria and forms are published at njmmis.com. Source: NJ DMAHS Pharmacy
California: Medi-Cal maintains the Contract Drug List with PA requirements for PCSK9 inhibitors, processed by Medi-Cal Rx (Magellan) for FFS beneficiaries. CA managed care plans (LA Care, Health Net, CalOptima, Partnership HealthPlan) maintain their own formularies with separate PA criteria. California SB 282 requires health plans to disclose PA criteria for any formulary drug within one business day of provider request. Source: Medi-Cal Rx
Key takeaway: Submitting a Repatha PA to the wrong MCO portal or without checking the state’s preferred PCSK9 product creates avoidable delays. Verify MCO-specific formulary status before every submission.
The Repatha Biosimilar Timeline and What It Means for PA
As of early 2026, no biosimilar for Repatha (evolocumab) has been approved in the United States. Amgen’s primary U.S. patents for evolocumab expire in 2027. The Supreme Court’s 2023 ruling invalidated some of Amgen’s broader PCSK9 antibody patents, but more specific formulation and manufacturing patents remain. Any biosimilar entry timing remains uncertain and will depend on FDA approvals, patent matters, and launch decisions; some analysts point to a 2027 to 2028 window, but no date is established.
If and when evolocumab biosimilars reach the market, formulary treatment will depend on individual payer policies. Some payers may add a biosimilar as a preferred product and move branded Repatha to non-preferred or non-formulary status, which could introduce new step-therapy or PA requirements; patients stable on Repatha could face new PA requirements if their payer changes formulary preference. Future biosimilar timing and formulary treatment remain uncertain.
Current competitive alternatives: · Praluent (alirocumab): another injectable PCSK9 inhibitor with similar PA requirements · Leqvio (inclisiran): a PCSK9-targeting siRNA with biannual dosing; some payers have begun adding inclisiran to PCSK9 step therapy requirements before approving Repatha
Track payer formulary announcements quarterly. Practices with documented PA workflows for evolocumab can adapt quickly by updating submission templates when formulary preferences shift.
Why Practices Outsource Cardiology Prior Authorization
PCSK9 inhibitor PA is not a standard drug authorization. It requires detailed clinical documentation, payer-specific criteria knowledge, step therapy exception workflows, and ongoing reauthorization tracking, which is why many practices route it to a dedicated cardiology prior authorization team.
JAMA Cardiology found that PCSK9 inhibitor PAs require 3-11 times more documentation items than other cardiometabolic drugs. A single Repatha PA submission takes 30-60 minutes when clinical records are gathered, the payer portal is accessed, and supporting documents are attached. If denied, the appeal and peer-to-peer review add another 2-4 hours. For a cardiology practice prescribing Repatha to 30+ patients, the workload consumes entire FTEs.
A full-time in-house PA coordinator typically runs $55,000 to $84,000 fully loaded per year, varying by location and benefits.
Staffingly’s specialty PA specialists work at $399/week (volume discounts to $299/week) with no benefits overhead, no training gaps, and one to two week onboarding. Approximately 68% cost savings compared to in-house hires.
What outsourced cardiology PA teams handle: · Repatha, Praluent, and Leqvio PAs across commercial, Medicare Part D, and Medicaid payers · Step therapy exception requests with clinical documentation · Denial follow-up, written appeals, and peer-to-peer review coordination · Reauthorization tracking with automated deadline alerts · Payer portal submissions across a broad range of EHR systems · Amgen SupportPlus and manufacturer patient assistance program coordination
Staffingly by the numbers: · 99.2% clean claim rate · 800+ healthcare providers served · SOC 2 Type II, ISO 27001, and HIPAA compliant, one to two week go-live
What Cardiology Practices Actually Say
Cardiology practice managers on Reddit’s r/cardiology and r/medicalbilling repeat the same themes: statin trial documentation rejected because doses and dates were not listed separately, FOURIER citations missing from medical necessity letters, and peer-to-peer reviews lost because the 5-day window closed before anyone flagged it. The recurring solution is a PCSK9-specific documentation template capturing every statin trial with drug name, start date, end date, max dose, and reason for discontinuation.
Across cardiology PA workflows, the practices that improve first-pass approvals tend to share the same habits: a Repatha-specific documentation template with ASCVD staging and FOURIER references, statin and ezetimibe trials logged separately with dates and doses, and denials flagged quickly so peer-to-peer reviews are scheduled inside the payer’s window. For a documented example of dedicated specialty-medication prior authorization in practice, read our endocrinology prior authorization success story , where a dedicated remote PA team processed authorizations for growth hormone, insulin pumps, CGMs, and specialty medications.
What Did We Learn?
- Repatha (evolocumab) commonly requires prior authorization across major payers, and PCSK9 inhibitors carried a 30.95% prescription rejection rate between 2015 and 2021. Proactive, complete documentation is one of the most effective ways to reduce avoidable denials.
- Step therapy is a leading denial trigger. Document each statin and ezetimibe trial separately with dates, doses, and clinical outcomes before submitting.
- Submit everything in the initial request. Incomplete submissions are a frequent cause of delays. Point eligible patients to Amgen SupportPlus for financial-support resources, subject to the program’s current terms.
- State Medicaid rules differ. New York, New Jersey, and California each maintain their own preferred drug lists and MCO formularies, so verify the patient’s specific MCO before every Repatha submission.
| Item | Details |
|---|---|
| 30.95% | PCSK9 inhibitor rejection rate, 2015-2021 |
| 8-12 wk | maximally tolerated statin trial required |
| 70 mg/dL | common LDL-C threshold for ASCVD |
| 24-48 hrs | typical drug PA turnaround benchmark, payer dependent |
| 80.7% | Medicare Advantage denials overturned on appeal |